Nitric Oxide Services, LLC

05/25/2026

05/21/2026

For the past 10+ years at Nitric Oxide Services, LLC, nearly every project we’ve worked on has been CUSTOM.

Not “cookie cutter.”
Not “plug-and-play.”
Not a generic CRO workflow recycled from one client to the next.

Custom science.
Custom analytics.
Custom formulation.
Custom FDA-oriented strategy.

That matters when you’re working with one of the most complex and reactive signaling molecules in biology: nitric oxide (NO).

🧪 Our team has worked across an enormous range of nitric oxide technologies and applications, including:

✔ Nitric oxide donors

✔ Nitrite/nitrate delivery systems

✔ Plasma-generated nitric oxide

✔ NO-loaded hydrogels

✔ Water-based NO stabilization systems

✔ Orthopedic and stent coating technologies

✔ Transdermal NO delivery platforms

✔ Exercise physiology & performance applications

✔ Wound healing and regenerative medicine

✔ Nutraceuticals and supplement development

✔ Pharmaceutical reformulation strategies

✔ PK/PD and release kinetics studies

✔ Stability and degradation profiling

✔ FDA-oriented preclinical assay development

We understand:

🔬 HOW nitric oxide is generated

🔬 WHEN it releases

🔬 WHY it degrades

🔬 WHAT conditions stabilize it

🔬 WHICH formulations improve delivery

🔬 HOW regulators will evaluate the data

And we don’t just theorize it.

We have real-world experience with:

⚙ FTIR

⚙ HPLC

⚙ UV-Vis

⚙ Mass spectrometry

⚙ Chemiluminescence nitric oxide analysis

⚙ Temperature and stability chambers

⚙ Controlled release systems

⚙ Custom buffer and pH-release profiling

⚙ Transdermal evaluation models

⚙ Non-animal testing approaches

⚙ GLP/ICH-aligned analytical strategies

One of the biggest mistakes companies make is waiting until AFTER FDA feedback to design the studies they should have done from the beginning.

Our philosophy is different:

➡ Design studies NOW that answer the questions regulators will eventually ask.

That approach has helped many of our clients move forward efficiently while avoiding expensive redevelopment cycles later.

And unlike many large CROs, we work collaboratively and pragmatically.

We build realistic budgets.
We stay flexible.
We communicate directly with clients.

And we tailor the science to YOUR technology.

If your company is developing ANYTHING involving nitric oxide — from pharmaceuticals and medical devices to nutraceuticals, biomaterials, plasma technologies, coatings, or delivery systems — we would love to discuss your project.

📞 Let’s build the right strategy together.

🌐 www.NitricOxideLab.com

04/29/2026

🚨 Featured Publication + Cover Recognition — A Major Milestone 🚨

We’re proud to announce that our latest peer-reviewed publication has been selected as a FEATURED ARTICLE and COVER FEATURE in the IJPC - International Journal of Pharmaceutical Compounding (IJPC) 🎉

👉 You can read the full issue by clicking “View Now” at IJPC.com

📄 Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency by Joseph A. Bauer, Ph.D., Dr. Annette Sysel, American HERO Veterinarian, DVM, MS, Bauer Research Foundation, Inc.; Michael Dunphy, Ph.D., Walsh University.

Why this matters 👇

Most people think compounding is simply turning liquids into creams or capsules…

It’s not.

Compounding is one of the most powerful, underappreciated tools in drug development — enabling delivery of therapeutics in ways patients can actually tolerate and use:

✔️ Transdermal instead of injections
✔️ Improved stability for fragile molecules
✔️ Customized dosing and delivery systems

What we demonstrated 🔬

In this study, we tackled a major challenge with nitrosylcobalamin (NO-Cbl) — a promising nitric oxide–based anticancer agent:

➡️ Poor solubility
➡️ Stability limitations
➡️ Delivery constraints

Using a nanoemulsion platform, we showed:

✅ Improved solubility and formulation concentration
✅ Enhanced stability under controlled conditions
✅ ~5-fold increase in anti-tumor potency in melanoma cells

Why this is exciting 💡

This isn’t just about one compound.

This is about a platform approach for difficult molecules — especially those with both hydrophilic and hydrophobic characteristics.

Nanoemulsions may:

✔️ Enable better membrane pe*******on
✔️ Reduce required dose
✔️ Potentially bypass receptor limitations (e.g., CD320 uptake)

✔️ Improve therapeutic outcomes

Our mission

At Nitric Oxide Services, LLC, this is exactly what we do:

🔬 Solve complex formulation challenges
📊 Provide validated analytical support
🧪 Design custom, fit-for-purpose studies
📈 Help move technologies from concept → data → publication → IP

This publication is a perfect example of that pipeline in action.

Let’s build something together

If you’re working on:

• Nitric oxide therapeutics
• Drug delivery challenges
• Topicals, injectables, or nanoformulations
• Wearables or novel platforms

📞 Let’s talk — we’ll help you get to an outcome.

04/18/2026

Not all CROs are built the same.

Most contract research organizations follow a fixed plan.

Once the protocol is signed… you’re locked in.

At Nitric Oxide Services, LLC, we take a different approach:

🔬 We start with your problem — not a template

🧠 We design practical, biologically relevant experiments

🔄 We adapt in real-time as data evolves

🤝 We collaborate with you throughout the project

Because real science isn’t linear—and neither are breakthrough results.

With 30+ years of nitric oxide expertise and PhD-level scientists leading every study, we focus on one thing:

👉 Translating science into practical, real-world applications

From therapeutics and biomaterials to supplements and delivery systems— we help you move from concept → data → impact.

✔ CLIA-certified laboratory

✔ SAM.gov registered

✔ Proven publication & IP track record

If you’re tired of rigid CRO models…

Let’s build something that actually works.

🌐 www.nitricoxidelab.com

04/12/2026

🧪 Unlike many CROs, TEAM NOS does not just run experiments — we help design them.

At Nitric Oxide Services, LLC, discovery and experimental design are part of the value we bring to every client relationship. 🔬 Our GLP and CLIA-certified laboratory specializes in bioanalytical nitric oxide evaluation, and our studies are carried out by trained Ph.D. scientists using proven, tried-and-true SOPs.

📈 We do not hand your project off and disappear.

🤝 We stay in close contact because real science evolves. When results suggest a better path forward, we communicate that promptly rather than rigidly following an outdated plan. That is a major advantage over traditional CRO models.

✅ The TEAM NOS advantage:

🧠 Experimental design and discovery support

👨‍🔬 Ph.D.-level scientific leadership

📋 Proven SOP-driven workflows

🏥 GLP and CLIA-certified capabilities

📞 Ongoing client communication and strategic input

🧬 Deep expertise in nitric oxide science

Behind the scenes, TEAM NOS has supported dozens of Fortune 500 companies while remaining at the forefront of nitric oxide science. 🌎 We also bring a proven track record of peer-reviewed publications that helps guide strategy, inspire innovation, and support client success.

When the science matters, experience matters.

🌐 https://nitricoxidelab.com/

📄 Request for Proposal: https://nitricoxidelab.com/request-for-proposal

04/10/2026

Nitrosylcobalamin (NO-Cbl) may offer a true double hit against cancer.

First, it is designed to exploit CD320-mediated uptake of cobalamin compounds, helping deliver NO-Cbl into tumor cells. Second, our newly published study showed that NO-Cbl can work synergistically with TRAIL and temozolomide, supporting its potential to enhance apoptotic signaling while countering resistance pathways.

In glioblastoma, that matters. Too often, patients receive standard chemotherapy in fixed cycles, only to face tumors that become less responsive over time. By contrast, NO-Cbl was developed as an NO-releasing cobalamin analog that selectively targets tumors through the transcobalamin II receptor (CD320) system, crossed the blood-brain barrier in this study, accumulated in tumor tissue, and showed synergy with both TRAIL and TMZ in glioma cells.

That is why this platform is so important: not just cytotoxic activity, but a strategy that may combine targeted uptake, apoptosis promotion, and suppression of survival signaling in one therapeutic approach. This mechanistic model is part of why we believe NO-Cbl deserves serious attention as a next-generation anticancer strategy.

Proud to share our publication in Oncoscience:

Selective blood-brain barrier pe*******on and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with TRAIL and temozolomide. Published April 2, 2026. DOI: 10.18632/oncoscience.654.

https://www.oncoscience.us/article/654/

04/07/2026

Are you developing a nitric oxide product, technology, or platform?

One of the biggest barriers to success in this space is the lack of rigorous analytical validation. Too many therapeutics, supplements, topicals, wearables, and device-based innovations struggle because the underlying data are not strong enough to support claims, publications, IP, or commercialization.

Nitric Oxide Services, LLC helps solve that problem.

For 10 years, we have supported clients with specialized nitric oxide analytics and translational R&D designed to generate credible, decision-driving data.

Our track record includes contributing to peer-reviewed scientific publications, supporting client IP, and helping innovators build stronger scientific foundations for growth.

If you need a trusted partner in nitric oxide testing and development, let’s talk.

Nitric Oxide Services, LLC
Validated nitric oxide analytics and translational R&D
nitricoxidelab.com

04/04/2026

We are extremely proud to announce the publication of our new paper in Oncoscience:

"Selective blood–brain barrier pe*******on and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with TRAIL and temozolomide."

https://www.oncoscience.us/article/654/

Glioblastoma remains one of the clearest unmet needs in oncology. For decades, patients have faced a treatment landscape built on the same basic backbone of surgery and radiation, with temozolomide later added as the major systemic standard. Yet despite this approach, recurrence remains common and durable clinical progress has been limited. That reality continues to highlight the urgent need for better, more selective therapies for GBM.

In this study, nitrosylcobalamin (NO-Cbl) demonstrated selective blood-brain barrier pe*******on, tumor targeting in glioblastoma tissue, and synergistic antiproliferative activity with both TRAIL and temozolomide in glioblastoma models. These findings support continued investigation of cobalamin-based nitric oxide therapeutics as a novel strategy for GBM.

This publication is deeply personal. The study is dedicated to the memory of Joseph Bauer, beloved father of the senior author, whose courageous battle with GBM and untimely passing following unsuccessful treatment with radiation and temozolomide served as the inspiration for this work. His experience underscores why the search for more effective targeted therapies is so important.

We are grateful to the research staff and technical teams who supported the in vivo and in vitro studies, with special appreciation to the laboratory of Michael A. Vogelbaum, MD, PhD (now at Moffitt Cancer Center) for conducting the animal experiments, Daniel J. Linder, MD, PhD (Cleveland Clinic) for supporting the evaluation of nitrosylcobalamin as an anticancer agent, and Avi Ashkenazi (Genentech) for the generous gift of TRAIL. We also acknowledge the foundational contributions of Dr. Daniel J. Smith (The University of Akron), Dr. Bellur Seetharam (Froedtert & the Medical College of Wisconsin), and Dr. Harry Hogenkamp (University of Minnesota Twin Cities), whose early work helped lay the groundwork for these discoveries.

For far too long, glioblastoma patients and families have faced a standard of care defined more by endurance than by meaningful therapeutic progress. We hope this work helps advance the development of new targeted options for patients confronting this devastating disease.

02/12/2026

✅ Nitric Oxide Services, LLC is now SAM.gov Registered (Federal Vendor Ready)
https://nitricoxidelab.com/

We’re excited to share that Nitric Oxide Services, LLC is officially registered in the U.S. federal government’s System for Award Management (SAM.gov)—making it easier for federal agencies, prime contractors, and SBIR/STTR teams to engage us for validated nitric oxide analytics and translational R&D support.

SAM.gov identifiers

• UEI: NRL8NCLSNVT9

• CAGE: 8LEU4

What we deliver (fast, validated, sponsor-ready):

🔸 CLIA-certified nitric oxide testing (clinical-grade reporting)

🔸 Chemiluminescence NOx / nitrate-nitrite panels and custom bioanalytical methods

🔸 NO-release kinetics (in vitro) + performance testing

🔸 Franz-cell permeation and topical/transdermal assessment

🔸 Fit-for-purpose study design for devices, drugs, and NO-based coatings

If you’re building a program where nitric oxide biology, NO delivery, or NO analytics matter—let’s talk. We support both direct awards and subcontracting under primes.

📩 Email: jbauer@nitricoxidelab.com

🌐 Search our UEI/CAGE on SAM.gov’s Entity Status Tracker to verify.

SAM registration reflects entity registration in a federal vendor system and does not imply U.S. Government endorsement.

10/09/2025

Thrilled to share our latest publication in Nitric Oxide:
“A Versatile Vanadium(III)-Based Chemiluminescence Protocol for Nitric Oxide Metabolite Quantification and NO Release Kinetics.”
🔗 https://pubmed.ncbi.nlm.nih.gov/41062015/

Nitric oxide (NO) is a critical signaling molecule at the intersection of cardiovascular, neurological, and immune health. Yet, its fleeting nature has long challenged efforts to measure it accurately in biological systems. Our work presents a robust, accessible, and cost-effective vanadium(III)-based chemiluminescence method that quantifies nitrate and nitrite — stable metabolites of NO — in biological fluids such as serum, urine, and cerebrospinal fluid.

By coupling this with headspace gas analysis, the method enables precise determination of NO release kinetics and half-life, allowing researchers and clinicians to better evaluate NO bioavailability and donor compound performance. The implications are broad — from monitoring endothelial function and sepsis progression to evaluating therapeutic efficacy and disease prevention strategies in personalized and translational medicine.

This work builds on decades of nitric oxide research and aims to make accurate NO metabolite analysis more routine across both diagnostic and research laboratories.
I extend sincere thanks to my co-authors Dr. Annette M. Sysel (Bauer Research Foundation, Inc.) and Dr. Michael J. Dunphy (Walsh UniversityWalsh University) for their collaboration and technical rigor.

Special appreciation to Alan and Ryan Kramme of Ace Glass Incorporated, Ken Thompson of Midwest Process Controls, and Dr. Daniel J. Smith of The University of Akron, whose foundational work inspired key refinements in this protocol.

Together, this represents a step forward toward making nitric oxide quantification more accessible — empowering researchers and clinicians to better prevent, monitor, and treat diseases rooted in NO imbalance.

Nitric oxide (NO) is a central mediator of vascular, neurological, and immune functions, and its dysregulation is implicated in a broad spectrum of diseases. Despite its significance, direct measurement of NO in human samples is limited by its transient nature and rapid conversion to nitrate and nit...

10/09/2025

Thrilled to share our latest publication in Nitric Oxide:

“A Versatile Vanadium(III)-Based Chemiluminescence Protocol for Nitric Oxide Metabolite Quantification and NO Release Kinetics.”

🔗 https://pubmed.ncbi.nlm.nih.gov/41062015/

Nitric oxide (NO) is a critical signaling molecule at the intersection of cardiovascular, neurological, and immune health. Yet, its fleeting nature has long challenged efforts to measure it accurately in biological systems. Our work presents a robust, accessible, and cost-effective vanadium(III)-based chemiluminescence method that quantifies nitrate and nitrite — stable metabolites of NO — in biological fluids such as serum, urine, and cerebrospinal fluid.

By coupling this with headspace gas analysis, the method enables precise determination of NO release kinetics and half-life, allowing researchers and clinicians to better evaluate NO bioavailability and donor compound performance. The implications are broad — from monitoring endothelial function and sepsis progression to evaluating therapeutic efficacy and disease prevention strategies in personalized and translational medicine.

This work builds on decades of nitric oxide research and aims to make accurate NO metabolite analysis more routine across both diagnostic and research laboratories.

I extend sincere thanks to my co-authors Dr. Annette M. Sysel (Bauer Research Foundation, Inc.) and Dr. Michael J. Dunphy (Walsh UniversityWalsh University) for their collaboration and technical rigor.

Special appreciation to Alan and Ryan Kramme of Ace Glass Incorporated, Ken Thompson of Midwest Process Controls, and Dr. Daniel J. Smith of The University of Akron, whose foundational work inspired key refinements in this protocol.

Together, this represents a step forward toward making nitric oxide quantification more accessible — empowering researchers and clinicians to better prevent, monitor, and treat diseases rooted in NO imbalance.

Nitric oxide (NO) is a central mediator of vascular, neurological, and immune functions, and its dysregulation is implicated in a broad spectrum of diseases. Despite its significance, direct measurement of NO in human samples is limited by its transient nature and rapid conversion to nitrate and nit...